References

1. Hughes TP, Kaeda J, Branford S, et al.: Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia. N Engl J Med 349(15):1423-1432, 2003.

2. O'Brien SG, Guilhot F, Larson RA, et al.: Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia.

3. Kantarjian H, Talpaz M, O'Brien S, et al.: High-dose ima-tinib mesylate therapy in newly diagnosed Philadelphia chromosome-positive chronic phase chronic myeloid leukemia. Blood 103(8):2873-2878, 2004.

4. Mahon FX, Deininger MW, Schultheis B, et al.: Selection and characterization of BCR-ABL positive cell lines with differential sensitivity to the tyrosine kinase inhibitor STI571: diverse mechanisms of resistance. Blood 96(3): 1070-1079, 2000.

5. le Coutre P, Tassi E, Varella-Garcia M, et al.: Induction of resistance to the Abelson inhibitor STI571 in human leukemic cells through gene amplification. Blood 95(5): 1758-1766, 2000.

6. Branford S, Rudzki Z, Walsh S, et al.: High frequency of point mutations clustered within the adenosine triphos-phate-binding region of BCR/ABL in patients with chronic myeloid leukemia or Ph-positive acute lym-phoblastic leukemia who develop imatinib (STI571) resistance. Blood 99(9):3472-3475, 2002.

7. Branford S, Rudzki Z, Walsh S, et al.: Detection of BCR-ABL mutations in patients with CML treated with ima-

against peptide-pulsed T2 cells, as well as significant lysis of BM cell at diagnosis but not at remission. This study provided evidence that peptide vaccination against PR1 of leukemia patients can elicit highly active specific cellular immunity against leukemia.

0 0

Post a comment